EP3503870A1 - Skin care composition - Google Patents

Skin care composition

Info

Publication number
EP3503870A1
EP3503870A1 EP17754154.7A EP17754154A EP3503870A1 EP 3503870 A1 EP3503870 A1 EP 3503870A1 EP 17754154 A EP17754154 A EP 17754154A EP 3503870 A1 EP3503870 A1 EP 3503870A1
Authority
EP
European Patent Office
Prior art keywords
lactobacillus
care composition
skin care
lactic acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17754154.7A
Other languages
German (de)
French (fr)
Inventor
Ursula Fritzmeier
Birgit LEWANDOWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georg Fritzmeier GmbH and Co KG
Original Assignee
Georg Fritzmeier GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg Fritzmeier GmbH and Co KG filed Critical Georg Fritzmeier GmbH and Co KG
Publication of EP3503870A1 publication Critical patent/EP3503870A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the invention relates to a skin care composition for the care of dry skin and for the relief of skin irritations.
  • the object of the invention is to achieve a skin care composition having an improved action for the care of dry skin and for the relief of skin irritations.
  • the presence of lactic acid bacteria in the normal flora of the intestine, skin and mucous membranes in humans and animals as well as their involvement in the formation and maintenance of a so-called protective shield on the skin is known.
  • the natural bacterial protective shield of the skin serves primarily to prevent the colonization of undesired microorganisms and thus to prevent a risk of infection (Georg Fuchs, Hans-Günter Schlegel, "General Microbiology", 8th Edition, Thieme Verlag (2006), p 354).
  • Lactic acid bacteria and lactic acid are therefore used in medical devices mainly to stabilize or restore them in case of disturbances or loss of the above-mentioned shield function. This is achieved by increasing and maintaining the lactic acid concentration on the skin or mucous membrane treated therewith so that the physiological pH is restored. Products relating to this are, for example, vaginal capsules or vaginal suppositories containing lactic acid bacteria and / or lactic acid.
  • EP 1995307 B1 discloses methods and means for protecting the skin from pathogenic microorganisms.
  • microorganisms of the species Lactobacillus buchneri and Lactobacillus delbgurii are used to inhibit the growth of specific pathogenic microorganisms without inhibiting the growth of Staphylococcus epidermidis attributed to the resident skin flora.
  • lactic acid bacteria used in toothpaste.
  • the active ingredient Pro-t- Action® developed by BASF and derived from lactic acid bacteria, is added to prevent the caries-producing bacterium Streptococcus mutans from adhering to the teeth.
  • lactic acid bacteria in products to be applied to the skin is limited in the prior art that it is intended to achieve or improve protection against pathogenic microorganisms.
  • the alleviation of skin irritation or a care effect on dry skin are not known.
  • a skin care composition comprising a vehicle and a proportion of lactic acid bacteria and / or their metabolites.
  • the skin care composition according to the invention has an excellent action to relieve skin irritation and is also excellent for the care of dry skin.
  • the lactic acid bacteria used in the present invention are cultured in a well known manner in a suitable nutrient solution.
  • the Lactobacillus ferment thus obtained is then used in the preparation of the skin care composition according to the invention.
  • the lactic acid bacteria may be contained in the skin care composition live or else only their metabolites.
  • the fermentation product obtained in the cultivation of the lactic acid bacteria is used either as such and thus together with the living cultures in the preparation of the skin care composition or, before use, the resulting ferment is subjected to a treatment whereby the living cultures are inactivated, ie killed.
  • thermal sterilization methods such as heat sterilization and physical sterilization methods such as radiation sterilization and sterile filtration may be cited.
  • the skin care composition according to the invention may contain both live cultures and inactive cultures of lactic acid bacteria.
  • the lactic acid bacteria are selected from one or more strains of Lactobacillus casei, Lactobacillus apis, Lactobacillus gasseri, Lactobacillus sakei, Lactobacillus lactis, Lactobacillus gastricus, Lactobacillus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus, Lactobacillus parabuchneri, Lactobacillus frumenti, Lactobacillus fermentum, Lactobacillus jensenii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus piscicola and Lactobacillus murinus.
  • the lactic acid bacteria are selected from one or more strains of Lactobacillus casei, Lactobacillus apis, Lactobacillus gasseri, Lactobacillus sakei, Lactobacillus lactis, Lactobacillus gastricus, Lactobacillus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus, Lactobacillus parabuchneri, Lactobacillus frumenti, Lactobacillus fermentum , Lactobacillus jensenii and Lactobacillus reuteri.
  • the lactic acid bacteria are particularly preferably selected from one or more strains of Lactobacillus casei, Lactobacillus apis, Lactobacillus gasseri, Lactobacillus sakei, Lactobacillus lactis, Lactobacillus gastricus, Lactobacillus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus and Lactobacillus parabuchneri. It is most preferred that the lactic acid bacteria of the Lactobacillus plantarum strain be.
  • the lactic acid bacterial mass fraction in the skin care composition of the present invention is about at least 0.1%, preferably about 1% to 10%, and most preferably about 5%.
  • the skin care composition additionally contains chitosan or a suitable chitosan derivative such as chitosan lactate. Chitosan can also act as the carrier.
  • the skin care effect can be further improved, even if a proportion of hyaluronic acid or a suitable Hyaluronklaivats is included.
  • the vehicle is preferably a cream.
  • This cream may be based on an oil-in-water emulsion or suspension. It is also possible to use a gel matrix.
  • the skin care composition of the present invention may be formulated, for example, in the form of a cream or a gel, as set forth above.
  • Further exemplary preparation types are a serum or a bath additive.
  • a serum according to the invention is usually characterized by being liquid, having a light texture and a relatively high proportion of active ingredient.
  • An inventive bath additive is usually also liquid.
  • the skin care composition according to the invention can also be used for the production of a care dressing or a wound dressing.
  • the composition according to the invention is introduced as a nourishing additive in a suitable carrier or applied to this.
  • the carrier mixed with the skin care composition according to the invention may be applied for application to the skin area to be groomed or treated. the.
  • the materials commonly used in dressings or wound dressings can be used, such as fabrics or nonwovens made of natural or artificial fibers or plastic films.
  • the carrier may consist of a single layer or be composed of several layers, which preferably consist of different materials.
  • the skin care composition according to the invention may contain, in addition to the lactic acid bacteria or their metabolites, one or more ingredients which aid the action of the skin care composition according to the invention or which themselves have a nourishing or soothing effect.
  • chitosan and hyaluronic acid can be mentioned.
  • the skin care composition of the present invention may commonly contain adjuvants used in cosmetic articles such as solvents, humectants and moisturizing agents, emollients, emulsifiers, gellants, stabilizers, antioxidants and buffers.
  • the solvent used is preferably water.
  • the effectiveness of the skin care composition according to the invention was tested by means of a UV erythema test on the human skin of six test persons.
  • the skin of each of the test persons was irradiated with UV-B light in such a way that a visible erythema (erythema) developed.
  • the reddened areas of the skin were then treated daily with three different products A, B and C over a period of seven days, leaving a fourth part of the skin without any treatment.
  • the reddening of the skin was measured daily by means of a chromameter and additionally evaluated by the respective test persons subjectively.
  • Product A was a cream containing live cultures of Lactobacillus plantarum, chitosan and water.
  • Product B was a cream containing inactive (killed) cultures. from Lactobacillus plantarum, chitosan and water.
  • Products A and B contained the lactobacilli in a proportion of 0.3% (w / v) and chitosan in the form of chitosan lactate (molecular weight 30,000-500,000 Da) in a proportion of 10% (w / v).
  • Product C was a commercial cream containing dexpanthenol as an active ingredient (Bepanthen® from BASF) and was a comparatively well-known comparative product. The three products used in the test were neutrally packaged so that none of them did Test persons could identify which of the products contained the ingredient to be tested or was a reference sample.
  • test fields each measuring 2 cm x 2 cm were marked on the six subjects with different skin types aged 24 to 41 years on the forearm inside.
  • the irradiation with UV-B light was carried out with the device UV802L / P / UV6 (Waldmann).
  • MED minimum erythema dose - corresponds to the minimum dose to reach erythema.
  • Each of the four test fields was irradiated with the same radiation intensity.
  • Test fields A, B and C were treated with products A, B and C, respectively.
  • Field D remained untreated for the duration of the experiment.
  • the application of the preparations was started 24 hours after the UV irradiation and then took place continuously once a day. Subjects were instructed not to use any other personal care products or to take sunbaths during this time.
  • the colorimeter Chromameter CR 200 of the company Minolta was used for the quantitative determination of the color changes on the human skin.
  • a flexible measuring head (diameter 1 cm) is placed on the skin area to be examined and the color nuances of the skin are measured by emitting a flash of light (CIE standard illuminant C).
  • CIE standard illuminant C the light reflected back from the skin is measured and represented numerically in the L * a * b color system.
  • the color coordinates a * and b * where the a * coordinate is the red-green color and the b * coordinate reflects the blue-yellow coloration.
  • an increasing a * value describes a Increased redness of the skin and a decreasing a * value indicates a fading of redness.
  • three measurements were taken in succession, which were averaged and stored by the device.
  • Table 2 shows for the days 1, 2, 3, 4 and 7 the results of the skin reddenings measured by means of the chromameter, whereby for each day an average of the individual measurements of the six test persons is indicated.
  • a * value is used, as this best reflects the redness of the skin.
  • a skin care composition according to the present invention has an effect of relieving skin irritation.
  • Such a composition also has the advantage that it can be prepared in a simple manner and is also well suited for the care of dry skin.
  • a skin care composition comprising a vehicle and a proportion of lactic acid bacteria or their metabolic products.

Abstract

The invention relates to a skin care composition, comprising a carrier substance and a fraction of lactic acid bacteria or of metabolic products thereof.

Description

Hautpflegezusammensetzung  Skin care composition
Beschreibung Die Erfindung betrifft eine Hautpflegezusammensetzung zur Pflege trockener Haut und zur Linderung von Hautirritationen. The invention relates to a skin care composition for the care of dry skin and for the relief of skin irritations.
Zur Pflege von trockener Haut oder zur Linderung von Hautirritationen wie einer Hautrötung oder eines Juckreizes werden unterschiedliche Pflegeprodukte eingesetzt, die jedoch nicht immer die gewünschte Pflegewirkung oder Linderung zeigen. To care for dry skin or to relieve skin irritation such as redness or itching different care products are used, but not always show the desired care effect or relief.
Demgegenüber liegt der Erfindung die Aufgabe zugrunde, eine Hautpflegezusammensetzung mit verbesserter Wirkung zur Pflege trockener Haut und zur Linderung von Hautirritationen zu erzielen. In contrast, the object of the invention is to achieve a skin care composition having an improved action for the care of dry skin and for the relief of skin irritations.
Das Vorkommen von Milchsäurebakterien in der normalen Flora von Darm, Haut und Schleimhäuten bei Mensch und Tier wie auch deren Beteiligung bei der Ausbildung und Aufrechterhaltung eines sogenannten Schutzschildes auf der Haut ist bekannt. Dabei dient der natürliche bakterielle Schutzschild der Haut vor allem dazu, die Ansiede- lung unerwünschter Mikroorganismen zu verhindern und somit einer Infektionsgefahr vorzubeugen (Georg Fuchs, Hans-Günter Schlegel,„Allgemeine Mikrobiologie", 8. Auflage, Thieme Verlag (2006), S. 354). The presence of lactic acid bacteria in the normal flora of the intestine, skin and mucous membranes in humans and animals as well as their involvement in the formation and maintenance of a so-called protective shield on the skin is known. The natural bacterial protective shield of the skin serves primarily to prevent the colonization of undesired microorganisms and thus to prevent a risk of infection (Georg Fuchs, Hans-Günter Schlegel, "General Microbiology", 8th Edition, Thieme Verlag (2006), p 354).
Milchsäurebakterien sowie Milchsäure werden in Medizinprodukten daher vor allem dazu eingesetzt, bei Störungen oder Verlust der oben genannten Schutzschildfunktion diese zu stabilisieren oder wiederherzustellen. Erreicht wird dies durch Erhöhen und Aufrechterhalten der Milchsäurekonzentration auf der damit behandelten Haut oder Schleimhaut, so dass der physiologische pH-Wert wieder hergestellt wird. Diesbezügliche Produkte sind beispielsweise Vaginalkapseln oder Vaginalzäpfchen, die Milchsäu- rebakterien und/oder Milchsäure enthalten. Lactic acid bacteria and lactic acid are therefore used in medical devices mainly to stabilize or restore them in case of disturbances or loss of the above-mentioned shield function. This is achieved by increasing and maintaining the lactic acid concentration on the skin or mucous membrane treated therewith so that the physiological pH is restored. Products relating to this are, for example, vaginal capsules or vaginal suppositories containing lactic acid bacteria and / or lactic acid.
Die EP 1995307 B1 offenbart Verfahren und Mittel zum Schutz der Haut vor krankheitserregenden Mikroorganismen. Im Speziellen werden Mikroorganismen der Spezies Lactobacillus buchneri und Lactobacillus delbrückii verwendet, um das Wachstum spezieller pathogener Mikroorganismen zu inhibieren ohne dabei das Wachstum von Staphylococcus epidermidis zu inhibieren, die der residenten Hautflora zugerechnet werden. EP 1995307 B1 discloses methods and means for protecting the skin from pathogenic microorganisms. In particular, microorganisms of the species Lactobacillus buchneri and Lactobacillus delbrückii are used to inhibit the growth of specific pathogenic microorganisms without inhibiting the growth of Staphylococcus epidermidis attributed to the resident skin flora.
Ferner ist die Verwendung von Milchsäurebakterien in Zahnpasta bekannt. Hierbei wird der von der BASF entwickelte und aus Milchsäurebakterien gewonnene Wirkstoff Pro-t-Action® zugesetzt, um das Karies erzeugende Bakterium Streptococcus mutans daran hindert, sich an die Zähne anzuheften. Furthermore, the use of lactic acid bacteria in toothpaste is known. In this process, the active ingredient Pro-t- Action® , developed by BASF and derived from lactic acid bacteria, is added to prevent the caries-producing bacterium Streptococcus mutans from adhering to the teeth.
Der Einsatz von Milchsäurebakterien in Produkten die auf die Haut aufzubringen sind beschränkt sich nach dem Stand der Technik darauf, dass damit ein Schutz gegen krankheitserregende Mikroorganismen erreicht oder verbessert werden soll. Die Linderung von Hautirritationen oder eine Pflegewirkung bei trockener Haut sind daraus nicht bekannt. The use of lactic acid bacteria in products to be applied to the skin is limited in the prior art that it is intended to achieve or improve protection against pathogenic microorganisms. The alleviation of skin irritation or a care effect on dry skin are not known.
Die oben genannte Aufgabe der vorliegenden Erfindung wird durch eine Hautpflegezusammensetzung mit einer Trägersubstanz und einem Anteil an Milchsäurebakterien und/oder deren Stoffwechselprodukte gelöst. The above object of the present invention is achieved by a skin care composition comprising a vehicle and a proportion of lactic acid bacteria and / or their metabolites.
Überraschender weise zeigte es sich, dass eine Hautpflegezusammensetzung mit Milchsäurebakterien die eingangs genannte Problematik besonders gut löst. So weist die erfindungsgemäße Hautpflegezusammensetzung eine ausgezeichnete Wirkung zur Linderung von Hautirritationen auf und ist zudem hervorragend zur Pflege von trockener Haut geeignet. Surprisingly, it has been found that a skin care composition with lactic acid bacteria solves the problem mentioned above particularly well. Thus, the skin care composition according to the invention has an excellent action to relieve skin irritation and is also excellent for the care of dry skin.
Die in der vorliegenden Erfindung verwendeten Milchsäurebakterien werden auf allgemein bekannte Weise in einer geeigneten Nährlösung kultiviert. Das dadurch erhaltene Lactobacillus-Ferment wird dann bei der Zubereitung der erfindungsgemäßen Haut- Pflegezusammensetzung verwendet. The lactic acid bacteria used in the present invention are cultured in a well known manner in a suitable nutrient solution. The Lactobacillus ferment thus obtained is then used in the preparation of the skin care composition according to the invention.
Dabei können die Milchsäurebakterien in der Hautpflegezusammensetzung lebend enthalten sein oder aber auch nur deren Stoffwechselprodukte. Im Speziellen wird dazu das bei der Kultivierung der Milchsäurebakterien erhaltene Ferment entweder als solches und somit zusammen mit den lebenden Kulturen bei der Zubereitung der Hautpflegezusammensetzung eingesetzt oder wird das erhaltene Ferment vor der Verwendung einer Behandlung unterzogen, durch die die lebenden Kulturen inaktiviert, d.h. abgetötet, werden. Hier können beispielhaft thermische Sterilisationsverfahren, wie Hitzesterilisation, und physikalische Sterilisationsverfahren, wie Strahlensterilisation und Sterilfiltration, genannt werden. The lactic acid bacteria may be contained in the skin care composition live or else only their metabolites. In particular, it will the fermentation product obtained in the cultivation of the lactic acid bacteria is used either as such and thus together with the living cultures in the preparation of the skin care composition or, before use, the resulting ferment is subjected to a treatment whereby the living cultures are inactivated, ie killed. Here, by way of example, thermal sterilization methods such as heat sterilization and physical sterilization methods such as radiation sterilization and sterile filtration may be cited.
In einer speziellen Ausführungsform kann die erfindungsgemäße Hautpflegezu- sammensetzung sowohl lebende Kulturen wie auch inaktive Kulturen der Milchsäurebakterien enthalten. In a specific embodiment, the skin care composition according to the invention may contain both live cultures and inactive cultures of lactic acid bacteria.
Vorzugsweise sind die Milchsäurebakterien ausgewählt aus einem oder mehreren Stämmen von Lactobacilllus casei, Lactobacilllus apis, Lactobacilllus gasseri, Lactobacilllus sakei, Lactobacilllus lactis, Lactobacilllus gastricus, Lactobacilllus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus, Lactobacilllus parabuchneri, Lactobacilllus frumenti, Lactobacilllus fermentum, Lactobacilllus jensenii, Lactobacilllus reuteri, Lactobacilllus rhamnosus, Lactobacilllus piscicola und Lactobacilllus murinus. Preferably, the lactic acid bacteria are selected from one or more strains of Lactobacillus casei, Lactobacillus apis, Lactobacillus gasseri, Lactobacillus sakei, Lactobacillus lactis, Lactobacillus gastricus, Lactobacillus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus, Lactobacillus parabuchneri, Lactobacillus frumenti, Lactobacillus fermentum, Lactobacillus jensenii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus piscicola and Lactobacillus murinus.
Weiter bevorzugt sind die Milchsäurebakterien ausgewählt aus einem oder mehreren Stämmen von Lactobacilllus casei, Lactobacilllus apis, Lactobacilllus gasseri, Lactobacilllus sakei, Lactobacilllus lactis, Lactobacilllus gastricus, Lactobacilllus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus, Lactobacilllus parabuchneri, Lactobacilllus frumenti, Lactobacilllus fermentum, Lactobacilllus jensenii und Lactobacilllus reuteri. More preferably, the lactic acid bacteria are selected from one or more strains of Lactobacillus casei, Lactobacillus apis, Lactobacillus gasseri, Lactobacillus sakei, Lactobacillus lactis, Lactobacillus gastricus, Lactobacillus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus, Lactobacillus parabuchneri, Lactobacillus frumenti, Lactobacillus fermentum , Lactobacillus jensenii and Lactobacillus reuteri.
Besonders bevorzugt sind die Milchsäurebakterien ausgewählt aus einem oder mehreren Stämmen von Lactobacilllus casei, Lactobacilllus apis, Lactobacilllus gasseri, Lactobacilllus sakei, Lactobacilllus lactis, Lactobacilllus gastricus, Lactobacilllus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus und Lactobacilllus parabuchneri. Dabei ist es am meisten bevorzugt, wenn die Milchsäurebakterien vom Stamm Lactobacillus plantarum sind. The lactic acid bacteria are particularly preferably selected from one or more strains of Lactobacillus casei, Lactobacillus apis, Lactobacillus gasseri, Lactobacillus sakei, Lactobacillus lactis, Lactobacillus gastricus, Lactobacillus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus and Lactobacillus parabuchneri. It is most preferred that the lactic acid bacteria of the Lactobacillus plantarum strain be.
Um eine ausreichende Wirkung der erfindungsgemäßen Hautpflegezusammen- Setzung sicherzustellen beträgt der Massenanteil an Milchsäurebakterien in der erfindungsgemäßen Hautpflegezusammensetzung ungefähr mindestens 0,1 %, vorzugsweise ungefähr 1 % bis 10 % und besonders bevorzugt etwa 5 %. In order to ensure a sufficient effect of the skin care composition of the present invention, the lactic acid bacterial mass fraction in the skin care composition of the present invention is about at least 0.1%, preferably about 1% to 10%, and most preferably about 5%.
In einer bevorzugten Ausführungsform enthält die Hautpflegezusammensetzung zu- sätzlich Chitosan oder ein geeignetes Chitosanderivat wie beispielsweise Chitosan- lactat. Dabei kann Chitosan auch als die Trägersubstanz fungieren. In a preferred embodiment, the skin care composition additionally contains chitosan or a suitable chitosan derivative such as chitosan lactate. Chitosan can also act as the carrier.
Die hautpflegende Wirkung lässt sich weiter verbessern, wenn auch ein Anteil an Hyaluronsäure oder eines geeigneten Hyaluronsäurederivats enthalten ist. The skin care effect can be further improved, even if a proportion of hyaluronic acid or a suitable Hyaluronsäurederivats is included.
Die Trägersubstanz ist vorzugsweise eine Creme. The vehicle is preferably a cream.
Diese Creme kann auf der Basis einer ÖI-in-Wasser-Emulsion oder -Suspension ausgebildet sein. Verwendbar ist auch eine Gelmatrix. This cream may be based on an oil-in-water emulsion or suspension. It is also possible to use a gel matrix.
Die erfindungsgemäße Hautpflegezusammensetzung kann, wie oben dargelegt, beispielsweise in der Forme einer Creme oder eines Gels zubereitet sein. Weitere beispielhafte Zubereitungsarten sind ein Serum oder ein Badezusatz. Ein erfindungsgemäßes Serum ist in der Regel dadurch charakterisiert, dass es flüssig ist, eine leichte Textur und einen relativ hohen Wirkstoffanteil aufweist. Ein erfindungsgemäßer Badezusatz ist in der Regel ebenfalls flüssig. The skin care composition of the present invention may be formulated, for example, in the form of a cream or a gel, as set forth above. Further exemplary preparation types are a serum or a bath additive. A serum according to the invention is usually characterized by being liquid, having a light texture and a relatively high proportion of active ingredient. An inventive bath additive is usually also liquid.
Gemäß einer speziellen Ausführungsform kann die erfindungsgemäße Hautpflegezusammensetzung auch zur Herstellung einer pflegenden Auflage oder einer Wund- aufläge verwendet werden. Dabei wird die erfindungsgemäße Zusammensetzung als pflegender Zusatz in einen geeigneten Träger eingebracht oder auf diesen aufgebracht. Der mit der erfindungsgemäßen Hautpflegezusammensetzung versetzte Träger kann zur Anwendung auf die zu pflegende oder zu behandelnde Hautpartie aufgelegt wer- den. Als Träger können die üblicherweise bei Auflagen oder Wundauflagen verwendeten Materialien verwendet werden wie beispielsweise Gewebe oder Vliesstoffe aus natürlichen oder künstlichen Fasern oder auch Kunststofffolien. Der Träger kann dabei aus einer Einzellage bestehen oder aber aus mehreren Lagen aufgebaut sein, wobei diese vorzugsweise aus verschiedenen Materialien bestehen. According to a specific embodiment, the skin care composition according to the invention can also be used for the production of a care dressing or a wound dressing. In this case, the composition according to the invention is introduced as a nourishing additive in a suitable carrier or applied to this. The carrier mixed with the skin care composition according to the invention may be applied for application to the skin area to be groomed or treated. the. As a carrier, the materials commonly used in dressings or wound dressings can be used, such as fabrics or nonwovens made of natural or artificial fibers or plastic films. The carrier may consist of a single layer or be composed of several layers, which preferably consist of different materials.
Weitere Vorteile und Merkmale der vorliegenden Erfindung ergeben sich anhand der folgenden ausführlichen Beschreibung, wobei zusätzlich auf bevorzugte Ausführungsbeispiele Bezug genommen wird. Further advantages and features of the present invention will become apparent from the following detailed description, wherein reference is additionally made to preferred embodiments.
Die erfindungsgemäße Hautpflegezusammensetzung kann zusätzlich zu den Milchsäurebakterien bzw. deren Stoffwechselprodukte einen oder mehrere Bestandteile enthalten, die die Wirkung der erfindungsgemäßen Hautpflegezusammensetzung unterstützen oder selbst eine pflegende oder lindernde Wirkung aufzeigen. Hierbei können unter anderem Chitosan und Hyaluronsäure genannt werden. The skin care composition according to the invention may contain, in addition to the lactic acid bacteria or their metabolites, one or more ingredients which aid the action of the skin care composition according to the invention or which themselves have a nourishing or soothing effect. Among others, chitosan and hyaluronic acid can be mentioned.
Ferner kann die erfindungsgemäße Hautpflegezusammensetzung üblicherweise in Kosmetikartikeln verwendete Hilfsstoffe enthalten wie Lösungsmittel, Humectants und feuchtigkeitsspendende Mittel, Emollientien, Emulgatoren, Gelbildner, Stabilisatoren, Antioxidantien und Puffer. Als Lösungsmittel wird vorzugsweise Wasser verwendet. Further, the skin care composition of the present invention may commonly contain adjuvants used in cosmetic articles such as solvents, humectants and moisturizing agents, emollients, emulsifiers, gellants, stabilizers, antioxidants and buffers. The solvent used is preferably water.
UV-Ervthemtest UV Ervthemtest
Die Wirksamkeit der erfindungsgemäßen Hautpflegezusammensetzung wurde anhand eines UV-Erythemtests an der menschlichen Haut von sechs Testpersonen über- prüft. Hierzu wurde die Haut eines jeden der Testpersonen derart mit UV-B-Licht bestrahlt, dass eine sichtbare Hautrötung (Erythem) entstand. Die geröteten Hautpartien wurden dann über einen Zeitraum von sieben Tagen täglich mit drei verschiedenen Produkten A, B und C behandelt, wobei eine vierte Hautpartie ohne jegliche Behandlung blieb. Die Hautrötung wurde täglich mittels eines Chromameters gemessen und zusätzlich von den jeweiligen Testpersonen subjektive bewertet. The effectiveness of the skin care composition according to the invention was tested by means of a UV erythema test on the human skin of six test persons. For this purpose, the skin of each of the test persons was irradiated with UV-B light in such a way that a visible erythema (erythema) developed. The reddened areas of the skin were then treated daily with three different products A, B and C over a period of seven days, leaving a fourth part of the skin without any treatment. The reddening of the skin was measured daily by means of a chromameter and additionally evaluated by the respective test persons subjectively.
Produkt A war eine Creme, die lebende Kulturen von Lactobacillus Plantarum, Chitosan und Wasser enthielt. Produkt B war eine Creme, die inaktive (abgetötete) Kultu- ren von Lactobacillus Plantarum, Chitosan und Wasser enthielt. Die Produkte A und B enthielten die Lactobacillen in einem Anteil von 0,3 % (w/v) und Chitosan in Form von Chitosanlactat (Molekulargewicht 30.000 - 500.000 Da) in einem Anteil von 10 % (w/v). Produkt C war eine im Handel erhältliche Creme, die als Wirkstoff Dexpanthenol enthielt (Bepanthen® von BASF), und stellte ein als gut wirkend bekanntes Vergleichsprodukt dar. Die in dem Test verwendeten drei Produkte waren neutral abgepackt, so dass keine der an der Durchführung des Tests beteiligten Personen erkennen konnte, welches der Produkte den zu testenden Inhaltstoff enthielt oder eine Vergleichsprobe war. Product A was a cream containing live cultures of Lactobacillus plantarum, chitosan and water. Product B was a cream containing inactive (killed) cultures. from Lactobacillus plantarum, chitosan and water. Products A and B contained the lactobacilli in a proportion of 0.3% (w / v) and chitosan in the form of chitosan lactate (molecular weight 30,000-500,000 Da) in a proportion of 10% (w / v). Product C was a commercial cream containing dexpanthenol as an active ingredient (Bepanthen® from BASF) and was a comparatively well-known comparative product. The three products used in the test were neutrally packaged so that none of them did Test persons could identify which of the products contained the ingredient to be tested or was a reference sample.
Im Speziellen wurde an den sechs Probanden unterschiedlichen Hauttyps im Alter von 24 bis 41 Jahren auf den Unterarminnenseiten vier Testfeldern in einer Größe von jeweils 2 cm x 2 cm markiert. Die Bestrahlung mit UV-B-Licht wurde mit dem Gerät UV802L/P/UV6 (Waldmann) durchgeführt. Für jeden Probanden wurde eine individuelle Bestrahlungszeit zur Erzeugung sichtbarer Erytheme gewählt, die dem 1 ,5 fachen seiner eigenen MED entsprach (MED = Minimale Erythem-Dosis - entspricht der Minimaldosis bis zum Erreichen einer Hautrötung). Jedes der vier Testfelder wurde mit der gleichen Strahlungsintensität bestrahlt. Die Testfelder A, B und C wurden mit den Produkten A, B bzw. C behandelt. Feld D blieb während der Versuchsdauer unbehandelt. Mit der Applikation der Präparate wurde 24 Stunden nach der UV-Bestrahlung begonnen und erfolgte dann fortlaufend einmal pro Tag. Die Probanden wurden angewiesen, während dieser Zeit keine anderen Pflegeprodukte zu benutzen und keine Sonnenbäder zu nehmen. In particular, four test fields each measuring 2 cm x 2 cm were marked on the six subjects with different skin types aged 24 to 41 years on the forearm inside. The irradiation with UV-B light was carried out with the device UV802L / P / UV6 (Waldmann). For each subject, an individual irradiation time was chosen to produce visible erythema, which was 1.5 times its own MED (MED = minimum erythema dose - corresponds to the minimum dose to reach erythema). Each of the four test fields was irradiated with the same radiation intensity. Test fields A, B and C were treated with products A, B and C, respectively. Field D remained untreated for the duration of the experiment. The application of the preparations was started 24 hours after the UV irradiation and then took place continuously once a day. Subjects were instructed not to use any other personal care products or to take sunbaths during this time.
Zur quantitativen Bestimmung der Farbveränderungen an der menschlichen Haut, hier der Hautrötungen, wurde das Farbmessgerät Chromameter CR 200 der Firma Minolta verwendet. Zur Messung wird ein flexibler Messkopf (Durchmesser 1 cm) auf das zu prüfende Hautareal gesetzt und durch Aussendung eines Lichtblitzes (CIE-Norm- lichtart C) die Farbnuancen der Haut gemessen. Mittels dreier Sensoren wird das von der Haut zurückgeworfene Licht gemessen und numerisch im L*a*b-Farbsystem dar- gestellt. Der Farbraum des L*a*b*- Systems ist durch die Helligkeit L* (wobei 100 = weiß; 0 = schwarz) und die Farbkoordinaten a* und b* gekennzeichnet, wobei die a*- Koordinate die Rot-Grün-Färbung und die b*-Koordinate die Blau-Gelb-Färbung wiedergibt. Bei zunehmender Rötung der Haut beschreibt ein steigender a*-Wert einen er- höhten Rotanteil der Haut und ein abnehmender a*-Wert kennzeichnet ein Verblassen der Hautrötung. Um mögliche Farbschwankungen im Messfeld zu minimieren, wurden jeweils drei Messungen hintereinander durchgeführt, die vom Gerät gemittelt und gespeichert wurden. For the quantitative determination of the color changes on the human skin, here the reddening of the skin, the colorimeter Chromameter CR 200 of the company Minolta was used. For measurement, a flexible measuring head (diameter 1 cm) is placed on the skin area to be examined and the color nuances of the skin are measured by emitting a flash of light (CIE standard illuminant C). By means of three sensors, the light reflected back from the skin is measured and represented numerically in the L * a * b color system. The color space of the L * a * b * system is characterized by the brightness L * (where 100 = white, 0 = black) and the color coordinates a * and b *, where the a * coordinate is the red-green color and the b * coordinate reflects the blue-yellow coloration. With increasing reddening of the skin, an increasing a * value describes a Increased redness of the skin and a decreasing a * value indicates a fading of redness. In order to minimize possible color fluctuations in the measuring field, three measurements were taken in succession, which were averaged and stored by the device.
Die Messungen wurden einmal pro Tag durchgeführt. Es wurde zudem von jeder der Testpersonen eine subjektive Bewertung hinsichtlich Rötung, Juckreiz und Wirkung des jeweiligen Testproduktes abgegeben. In Tabelle 1 ist der Zeitplan der Produktanwendungen, Messungen und Bewertungen aufgeführt. The measurements were carried out once a day. It was also submitted by each of the subjects a subjective assessment of redness, itching and effect of each test product. Table 1 lists the schedule of product applications, measurements and ratings.
Tabelle 1 : 2.1 Zeitplan der Produktanwendungen, Messungen und Bewertungen Table 1: 2.1 Schedule of Product Applications, Measurements and Ratings
Bei dermatologische Untersuchungen vor während und nach dem Test zeigten sich bei keiner der Testpersonen pathologische Hautveränderungen im Bereich des Test- areals. Die genannten Präparate wurden sehr gut vertragen und führten bei keiner Testperson zu unerwünschten Hautveränderungen. In dermatological examinations before and after the test, none of the subjects showed pathological lesions in the area of the test area. The preparations mentioned were very well tolerated and did not lead to any unwanted skin changes in any test subject.
Die nachfolgende Tabelle 2 zeigt für die Tage 1 , 2, 3, 4 und 7 die Ergebnisse der mittels des Chromameters gemessenen Hautrötungen, wobei für jeden Tag ein Mittel- wert über die einzelnen Messungen der sechs Probanden angegeben wird. Hierbei wird nur der a*-Wert herangezogen, da dieser die Rötung der Haut am besten wiederspiegelt. Table 2 below shows for the days 1, 2, 3, 4 and 7 the results of the skin reddenings measured by means of the chromameter, whereby for each day an average of the individual measurements of the six test persons is indicated. Here, only the a * value is used, as this best reflects the redness of the skin.
Für einen besseren Vergleich der Stärke der Hautrötung nach der Bestrahlung wird für den Tag 1 diese in Relation zu dem a*-Wert vor der Bestrahlung angegeben. Für die Tage 2, 3, 4 und 7 wird der gemessene a*-Wert in Relation zu dem Wert des maximalen Erytehms (24 h nach Bestrahlung) angegeben, um so einen Wert darzustellen, der der relativen Abnahme der Hautrötung entspricht. Tabelle 2: Zusammenfassende Darstellung der Chromameter-Messungen (a*-Wert) For a better comparison of the severity of reddening of the skin after irradiation, this is given for day 1 in relation to the a * value before irradiation. For the Days 2, 3, 4 and 7, the measured a * value is given in relation to the value of the maximum Erytehms (24 hours after irradiation) so as to represent a value corresponding to the relative decrease in reddening of the skin. Table 2: Summary of Chromameter Measurements (a * value)
Mit den nachfolgenden Tabellen werden die Ergebnisse der subjektiven Beurteilungen der Probanden hinsichtlich der Rötung, des Juckreizes und der Wirkung der einzelnen Produkte zusammengefasst. Die Bewertungen basieren auf einer 10-stufigen Skala (wobei 1 = nicht vorhanden; 10 = sehr stark; bzw. für Wirkung des Produktes: 1 = keine spürbare Wirkung; 10 = sehr gute Wirkung). The tables below summarize the results of the subjects' subjective assessments of redness, itching and the effect of each product. The ratings are based on a 10-step scale (where 1 = not available, 10 = very strong, or for effect of the product: 1 = no noticeable effect, 10 = very good effect).
Zudem bedeuten: * = vor der Bestrahlung; ** = maximales Erythem. In addition: * = before irradiation; ** = maximum erythema.
Tabelle 3.1 : Subjektive Beurteilungen Proband 1 Table 3.1: Subjective assessments Subject 1
Tabelle 3.2: Subjektive Beurteilungen Proband 2 Table 3.2: Subjective assessments Subject 2
Tag 0* Tag 1 " Tag 2 Tag 3 Tag 4 Tag 5 Tag 6 Tag 7Day 0 * Day 1 " Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Feld A Field A
Rötung 1 9 6 5 4 3 2 2 Redness 1 9 6 5 4 3 2 2
Juckreiz 1 4 2 1 1 1 1 1Itching 1 4 2 1 1 1 1 1
Wirkung des Effect of
5 5 5 5 5 3 3 Produkts  5 5 5 5 5 3 3 Products
Feld B  Field B
Rötung 1 9 7 6 4 4 2 2 Redness 1 9 7 6 4 4 2 2
Juckreiz 1 4 2 1 1 1 1 1Itching 1 4 2 1 1 1 1 1
Wirkung des Effect of
5 4 4 4 4 3 3 Produkts  5 4 4 4 4 3 3 Products
Feld C  Field C
Rötung 1 9 7 5 4 3 2 2 Redness 1 9 7 5 4 3 2 2
Juckreiz 1 4 2 1 1 1 1 1Itching 1 4 2 1 1 1 1 1
Wirkung des Effect of
5 6 6 5 5 3 3 Produkts  5 6 6 5 5 3 3 Products
Feld D  Field D
Rötung 1 9 8 6 5 4 3 2 Redness 1 9 8 6 5 4 3 2
Juckreiz 1 4 2 1 1 1 1 1 Tabelle 3.3: Subjektive Beurteilungen Proband 3 Itching 1 4 2 1 1 1 1 1 Table 3.3: Subjective assessments Subject 3
Tabelle 3.4: Subjektive Beurteilungen Proband 4 Table 3.4: Subjective assessments Subject 4
Tag 0* Tag 1 " Tag 2 Tag 3 Tag 4 Tag 5 Tag 6 Tag 7Day 0 * Day 1 " Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Feld A Field A
Rötung 1 9 5 4 3 2 2 2 Redness 1 9 5 4 3 2 2 2
Juckreiz 1 5 2 1 1 1 1 1Itching 1 5 2 1 1 1 1 1
Wirkung des Effect of
2 4 7 7 7 7 7 Produkts  2 4 7 7 7 7 7 Products
Feld B  Field B
Rötung 1 9 6 5 3 2 2 1 Redness 1 9 6 5 3 2 2 1
Juckreiz 1 5 2 1 1 1 1 1Itching 1 5 2 1 1 1 1 1
Wirkung des Effect of
2 3 5 7 7 7 8 Produkts  2 3 5 7 7 7 8 Products
Feld C  Field C
Rötung 1 9 7 7 5 4 3 2 Redness 1 9 7 7 5 4 3 2
Juckreiz 1 5 2 1 1 1 1 1Itching 1 5 2 1 1 1 1 1
Wirkung des Effect of
2 2 4 5 5 6 7 Produkts  2 2 4 5 5 6 7 Products
Feld D  Field D
Rötung 1 9 7 7 5 4 3 2 Redness 1 9 7 7 5 4 3 2
Juckreiz 1 5 2 1 1 1 1 1 Tabelle 3.5: Subjektive Beurteilungen Proband 5 Itching 1 5 2 1 1 1 1 1 Table 3.5: Subjective assessments Subject 5
Tabelle 3.6: Subjektive Beurteilungen Proband 6 Table 3.6: Subjective assessments Subject 6
Tag 0* Tag 1 " Tag 2 Tag 3 Tag 4 Tag 5 Tag 6 Tag 7Day 0 * Day 1 " Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Feld A Field A
Rötung 1 5 4 2 2 2 1 1 Redness 1 5 4 2 2 2 1 1
Juckreiz 1 3 2 1 1 1 1 1Itching 1 3 2 1 1 1 1 1
Wirkung des Effect of
1 1 5 5 3 1  1 1 5 5 3 1
Produkts 1 Product 1
Feld B Field B
Rötung 1 5 4 2 2 2 1 1 Redness 1 5 4 2 2 2 1 1
Juckreiz 1 3 2 1 1 1 1 1Itching 1 3 2 1 1 1 1 1
Wirkung des Effect of
1 1 5 5 3 1  1 1 5 5 3 1
Produkts 1 Product 1
Feld C Field C
Rötung 1 8 8 5 4 3 2 1 Redness 1 8 8 5 4 3 2 1
Juckreiz 1 4 2 1 1 1 1 1Itching 1 4 2 1 1 1 1 1
Wirkung des Effect of
1 1 5 5 4 2  1 1 5 5 4 2
Produkts 1 Product 1
Feld D Field D
Rötung 1 8 8 5 4 4 1 1 Redness 1 8 8 5 4 4 1 1
Juckreiz 1 4 3 1 1 1 1 1 Die in der Tabelle 1 dargestellten Ergebnisse der Chromameter-Messungen (a*- Wert) zeigen deutlich, dass im Vergleich zum unbehandelten Testfeld bei allen Produkten eine rötungsvermindernde Wirkung feststellbar war. Die subjektiven Beurteilungen der sechs Probanden zeigen ebenfalls, dass durch die Anwendung der Produkte die Rötung schneller zurückging und auch in einigen Fällen (Probanden 3 und 5) der Juckreiz weniger lang anhielt. Zudem wurde die Wirkung der erfindungsgemäßen Produkte A und B, die lebende bzw. inaktive Kulturen von Lac- tobacillus Plantarum enthielten, von den Probanden in der Regel zumindest gleich gut eingeschätzt wie das als gut wirkend bekannte kommerzielle Produkt C mit dem Wirkstoff Dexpanthenol. Ein weiterer Vorteil der erfindungsgemäßen Hautpflegezusammensetzung liegt darin, dass auf den Zusatz eines synthetischen Wirkstoffs verzichtet werden kann. Es konnte somit gezeigt werden, dass eine Hautpflegezusammensetzung gemäß der vorliegenden Erfindung eine Wirkung zur Linderung von Hautirritationen aufzeigt. Eine derartige Zusammensetzung hat zudem den Vorteil, dass sie auf einfache Weise herstellbar ist und auch gut zur Pflege von trockener Haut geeignet ist. Offenbart ist eine Hautpflegezusammensetzung mit einer Trägersubstanz und einem Anteil von Milchsäurebakterien oder von deren Stoffwechselprodukten. Itching 1 4 3 1 1 1 1 1 The results of the chromameter measurements (a * value) shown in Table 1 clearly show that a reddening effect was detectable in all products compared to the untreated test field. The subjective assessments of the six subjects also show that the application of the products decreased the redness faster and in some cases (subjects 3 and 5) the itching lasts less long. In addition, the effect of the products A and B according to the invention, which contained living or inactive cultures of Lacobacillus plantarum, was as a rule at least as well estimated by the test persons as the well-known commercial product C with the active ingredient dexpanthenol. A further advantage of the skin care composition according to the invention is that the addition of a synthetic active substance can be dispensed with. Thus, it has been demonstrated that a skin care composition according to the present invention has an effect of relieving skin irritation. Such a composition also has the advantage that it can be prepared in a simple manner and is also well suited for the care of dry skin. Disclosed is a skin care composition comprising a vehicle and a proportion of lactic acid bacteria or their metabolic products.

Claims

Patentansprüche claims
1 . Hautpflegezusannnnensetzung mit einer Trägersubstanz und einem Anteil an Milchsäurebakterien und/oder deren Stoffwechselprodukten. 1 . Skin care composition with a carrier substance and a proportion of lactic acid bacteria and / or their metabolic products.
2. Hautpflegezusammensetzung nach Patentanspruch 1 , wobei die Milchsäurebakterien ausgewählt sind aus Lactobacilllus casei, Lactobacilllus apis, Lactobacilllus gasseri, Lactobacilllus sakei, Lactobacilllus lactis, Lactobacilllus gastricus, Lactobacilllus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus, Lactobacilllus parabuchneri, Lactobacilllus frumenti, Lactobacilllus fermentum, Lactobacilllus jensenii, Lactobacilllus reuteri, Lactobacilllus rhamnosus, Lactobacilllus piscicola und Lactobacilllus murinus. The skin care composition according to claim 1, wherein the lactic acid bacteria are selected from Lactobacillus casei, Lactobacillus apis, Lactobacillus gasseri, Lactobacillus sakei, Lactobacillus lactis, Lactobacillus gastricus, Lactobacillus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus, Lactobacillus parabuchneri, Lactobacillus frumenti, Lactobacillus fermentum, Lactobacillus jensenii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus piscicola and Lactobacillus murinus.
3. Hautpflegezusammensetzung nach Patentanspruch 1 oder 2, wobei die Milchsäu- rebakterien vom Stamm Lactobacillus plantarum sind. 3. Skin care composition according to claim 1 or 2, wherein the lactic acid bacteria are of the strain Lactobacillus plantarum.
4. Hautpflegezusammensetzung nach einem der vorhergehenden Patentansprüche, wobei der Massenanteil an Milchsäurebakterien ungefähr mindestens 0,1 %, vorzugsweise ungefähr 1 % bis 10 % und besonders bevorzugt etwa 5 % beträgt. A skin care composition according to any one of the preceding claims wherein the lactic acid bacterial mass fraction is at least about 0.1%, preferably about 1% to 10% and most preferably about 5%.
5. Hautpflegezusammensetzung nach einem der vorhergehenden Patentansprüche, wobei die Milchsäurebakterien in Form lebender Kulturen enthalten sind. 5. Skin care composition according to one of the preceding claims, wherein the lactic acid bacteria are contained in the form of living cultures.
6. Hautpflegezusammensetzung nach einem der vorhergehenden Patentansprüche, wobei die Milchsäurebakterien in Form inaktiver Kulturen enthalten sind. A skin care composition according to any one of the preceding claims, wherein the lactic acid bacteria are in the form of inactive cultures.
7. Hautpflegezusammensetzung nach einem der vorhergehenden Patentansprüche, mit einem Anteil an Chitosan. 7. Skin care composition according to one of the preceding claims, with a proportion of chitosan.
8. Hautpflegezusammensetzung nach einem der vorhergehenden Patentansprüche, mit einem Anteil an Hyaluronsäure. 8. Skin care composition according to one of the preceding claims, with a content of hyaluronic acid.
9. Hautpflegezusannnnensetzung nach einem der vorhergehenden Patentansprüche, wobei die Trägersubstanz eine Creme ist. A skin care composition according to any one of the preceding claims, wherein the vehicle is a cream.
10. Hautpflegezusammensetzung nach Patentanspruch 9, wobei die Creme auf eine Emulsion oder Dispersion auf ÖI-in-Wasser-Basis oder eine Gelmatrix ist. The skin care composition of claim 9 wherein the cream is an oil-in-water emulsion or dispersion or a gel matrix.
EP17754154.7A 2016-08-24 2017-08-16 Skin care composition Withdrawn EP3503870A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102016115680 2016-08-24
DE102017103850.7A DE102017103850A1 (en) 2016-08-24 2017-02-24 Skin care composition
PCT/EP2017/070778 WO2018036882A1 (en) 2016-08-24 2017-08-16 Skin care composition

Publications (1)

Publication Number Publication Date
EP3503870A1 true EP3503870A1 (en) 2019-07-03

Family

ID=61167399

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17754154.7A Withdrawn EP3503870A1 (en) 2016-08-24 2017-08-16 Skin care composition

Country Status (4)

Country Link
US (1) US11357720B2 (en)
EP (1) EP3503870A1 (en)
DE (1) DE102017103850A1 (en)
WO (1) WO2018036882A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220340945A1 (en) * 2019-10-11 2022-10-27 National Uninversity Corporation Shizuoka University Lactic acid bacteria that produce nicotinamide riboside, and lactic acid bacteria that produce nicotinamide mononucleotide and nicotinamide riboside
AT17326U1 (en) 2021-03-29 2021-12-15 Sanubiom Gmbh A skin care composition in powder form from which a gel is made
WO2023106376A1 (en) * 2021-12-09 2023-06-15 国立大学法人九州大学 Collagen production promoter, hyaluronic acid production promoter, and epidermal keratinocyte activator

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736537A1 (en) 2005-06-22 2006-12-27 OrganoBalance GmbH Methods and means for protecting the skin against pathogenic microorganisms
FR2889057B1 (en) 2005-08-01 2008-07-18 Oreal COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF SENSITIVE OR DRY SKINS
WO2008018143A1 (en) * 2006-08-10 2008-02-14 House Wellness Foods Corporation Moisturizing agent
FR2942719B1 (en) * 2009-03-04 2011-08-19 Oreal USE OF PROBIOTIC MICROORGANISMS TO LIMIT SKIN IRRITATION
KR101640744B1 (en) 2014-05-07 2016-07-19 일동제약주식회사 Macromolecular polysaccharide binder conjugated Lactobacillus rhamnosus RHT-3201, and use thereof in prevention and treatment of atopic dermatitis

Also Published As

Publication number Publication date
WO2018036882A1 (en) 2018-03-01
DE102017103850A1 (en) 2018-03-01
US11357720B2 (en) 2022-06-14
US20190183783A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
DE69822546T2 (en) Cosmetic or pharmaceutical composition containing a culture medium of a microorganism
EP1269983B1 (en) Use of 1,2-Decanediol against germs which cause body malodour
EP2705140B1 (en) Novel lactic acid bacteria and compositions containing them
DE69919950T2 (en) Cosmetic composition containing a polysaccharide of a hydrothermal bacterium
CN110585076A (en) Prebiotics and probiotic composition, and preparation method and application thereof
DE102011119033A1 (en) Use of a composition comprising isosorbide caprylate/caprate in antiperspirant and deodorant to improve their effect for reducing the body odor
EP3362038A1 (en) Cosmetic composition having probiotic bacteria
EP3503870A1 (en) Skin care composition
EP3494850B1 (en) Wet wipe with hydroxyacetophenon
DE69916695T2 (en) Use of at least one hydroxystilbene as an agent for reducing the adhesion of microorganisms
KR102160980B1 (en) Cosmetic materials composition for controlling sebum and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof
DE102007026156B4 (en) Cosmetic composition with a limnocitrus littoralis extract
DE202016007098U1 (en) Cream with spirulina algae
EP2386309B1 (en) Bulbine frutescens gel
EP1458334B1 (en) Yeast-based curative and care product and method for making same
DE1492023C3 (en) Skin care products
CN110711263A (en) Functional dressing with functions of preventing, repairing and modifying scars and preparation method thereof
EP2347797A2 (en) Cosmetic method
DE102018106331A1 (en) Bacteria comprehensive composition for odor reduction
EP2658512A2 (en) Use of 13-hydroxy-9,11-octadecadienoic acid for tanning human skin, for dyeing human hair and for treating polymorphous light dermatosis
EP2638933A1 (en) Cosmetic products for skin ageing
DE102007028028A1 (en) Oxygen in cosmetic or dermatological preparations
CH694753A5 (en) Medicament for treating tumors and skin diseases comprises a water-buffalo milk product
DE112021002353T5 (en) Natural composition for hair growth stimulation and hair loss prevention and treatment
DE102022108329A1 (en) Composition for treating the skin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20190319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20191104

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603